2-(1H-benzimidazol-2-ylsulfanylmethyl)-5-phenyl-3H-thieno[2,3-d]pyrimidin-4-one | 726164-74-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2-(1H-benzimidazol-2-ylsulfanylmethyl)-5-phenyl-3H-thieno[2,3-d]pyrimidin-4-one
• CAS: 726164-74-5
• 化学式: C₂₀H₁₄N₄OS₂
• 分子量: 390.489
• InChiKey: HNVWOIYRIQMRJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(1H-benzimidazol-2-ylsulfanylmethyl)-5-phenyl-3H-thieno[2,3-d]pyrimidin-4-one 在 三氯氧磷 作用下， 以 2,2,2-三氟乙醇 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and biological evaluation of novel condensed pyrimidinylmethylsulfinylbenzimidazoles as antiulcer agent

  摘要：

  Current therapies to treat gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and other acid-related diseases either prevent stimulation of the parietal cell (H-2-receptor antagonists) or inhibit gastric H+/K+-ATPase (proton pump inhibitors). The inhibition of acid production by proton pump inhibitors (PPI's) provides more effective relief of symptoms and healing. A series of novel 4-substituted-2-(1H-benzimidazol-2-yl)methylsulfinylpyrimidines were synthesized as target compounds and antiulcer activity was done using parameters like total acidity, pH, and total gastric acid volume by pylorus ligation method on Wistar rats. Three different dose levels were employed for testings. The target compounds 4-substituted-2-(1H-benzimidazol-2-yl)methylsulfinylpyrimidines were effective for ulcer treatment and among them compounds 10c, 10d, 8b, and 8c exhibited potent antisecretory activity. Overall, compounds 10c, 10d, 8b, and 8c can be looked upon as potential leads for further development and investigations.

  DOI：

  10.1007/s00044-012-0358-6
• 作为产物：
  描述：

  2-氨基-4-苯基噻吩-3-羧酸乙酯 在 盐酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 生成 2-(1H-benzimidazol-2-ylsulfanylmethyl)-5-phenyl-3H-thieno[2,3-d]pyrimidin-4-one
  参考文献：
  名称：

  Synthesis and biological evaluation of novel condensed pyrimidinylmethylsulfinylbenzimidazoles as antiulcer agent

  摘要：

  Current therapies to treat gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and other acid-related diseases either prevent stimulation of the parietal cell (H-2-receptor antagonists) or inhibit gastric H+/K+-ATPase (proton pump inhibitors). The inhibition of acid production by proton pump inhibitors (PPI's) provides more effective relief of symptoms and healing. A series of novel 4-substituted-2-(1H-benzimidazol-2-yl)methylsulfinylpyrimidines were synthesized as target compounds and antiulcer activity was done using parameters like total acidity, pH, and total gastric acid volume by pylorus ligation method on Wistar rats. Three different dose levels were employed for testings. The target compounds 4-substituted-2-(1H-benzimidazol-2-yl)methylsulfinylpyrimidines were effective for ulcer treatment and among them compounds 10c, 10d, 8b, and 8c exhibited potent antisecretory activity. Overall, compounds 10c, 10d, 8b, and 8c can be looked upon as potential leads for further development and investigations.

  DOI：

  10.1007/s00044-012-0358-6

文献信息

• Synthesis and biological evaluation of novel condensed pyrimidinylmethylsulfinylbenzimidazoles as antiulcer agent
  作者：Prashik B. Dudhe、Kishor S. Jain、Vikas K. Raskar、Atul S. Deodhe、Jasminkumar G. Patel、Manisha S. Phoujdar、Muthu K. Kathiravan

  DOI：10.1007/s00044-012-0358-6

  日期：2013.8

  Current therapies to treat gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and other acid-related diseases either prevent stimulation of the parietal cell (H-2-receptor antagonists) or inhibit gastric H+/K+-ATPase (proton pump inhibitors). The inhibition of acid production by proton pump inhibitors (PPI's) provides more effective relief of symptoms and healing. A series of novel 4-substituted-2-(1H-benzimidazol-2-yl)methylsulfinylpyrimidines were synthesized as target compounds and antiulcer activity was done using parameters like total acidity, pH, and total gastric acid volume by pylorus ligation method on Wistar rats. Three different dose levels were employed for testings. The target compounds 4-substituted-2-(1H-benzimidazol-2-yl)methylsulfinylpyrimidines were effective for ulcer treatment and among them compounds 10c, 10d, 8b, and 8c exhibited potent antisecretory activity. Overall, compounds 10c, 10d, 8b, and 8c can be looked upon as potential leads for further development and investigations.